RANKL Antibody for Acute Charcot Neuro-osteoarthropathy (DANCN-CKD)

RANKL Antibody (Danosumab) for Acute Charcot Neuro-osteoarthropathy Remission in Chronic Kidney Disease

This study's goal was to determine how denosumab 60 mg, combined with total contact casting and restricted weightbearing status, would affect the treatment of acute CN with CKD.

METHODS Participants in the research were those who visited the outpatient foot clinic at PGIMER, CHD in India. During the study period, 446 persons with CN were identified, 102 of whom met the criteria for the first screening, and 78 of whom were ultimately enrolled in the study.

Aim: To assess the clinico-radiological remission of Acute Charcot-neuroarthropathy in patients of CKD.

Study Overview

• Status: Completed
• Conditions: Charcot Joint of Foot
• Intervention / Treatment: Drug: Danosumab; Other: Normal Saline

Detailed Description

Participants attending the outpatient diabetic foot facility of tertiary care hospital in North India were assessed for active CN. An active CN of the foot was considered in the presence of localised erythema, edoema, and a temperature differential of more than 20C compared to a similar location on the opposite foot. Participants were diagnosed with "active on chronic" CN if they met the requirements for active CN in the context of foot deformities suggestive of chronic CN (rocker bottom deformity). Those with self-reported diabetes or those who were already receiving treatment for diabetes, with an estimated glomerular filtration rate (eGFR) <60 ml/min/m2 (CKD-EPI equation) and more than 500 mg of urine protein/24 hours were considered as having diabetic CKD. Patients with active pedal ulcer, inactive charcot foot, peripheral vascular disease (ankle brachial index ABI <0.9), prior exposure to medications affecting bone metabolism particularly bisphosphonates, teriparatide, denosumab or steroids in the past 12 months, hypocalcemia, active malignancy, CKD on dialysis and pregnancy or lactating women were excluded. The study was conducted in accordance with the Declaration of Helsinki and its amendments, the International Conference on Harmonization Good Clinical Practice guidelines, and its applicable regulatory requirements. All participants provided their signed, fully informed consent and study protocol was approved by the institutional Ethics Committee ref INT/IEC/SPE-1664.

The foot temperature was determined by an infrared dermal thermometry [(FLIR Systems Inc, Orlando, USA) with a pixel resolution of 4800 (80*60), thermal sensitivity of 0.15 C, and a detection range of -20 C to 250 C] after 30 minutes of removing footwear or cast. X-ray and/or magnetic resonance imaging (MRI) were used to confirm the diagnosis of an active CN (3T scanner Siemens MagnetromVerio). The involved area of foot was classified anatomically for pattern of involvement using the Sanders-Frykberg classification. Clinical information was documented, including the duration of the symptoms, duration of diabetes, concomitant microvascular and macrovascular complications. Comprehensive neurological testing included vibration perception threshold (VPT>25 mV was considered abnormal) by biothesiometer-Vibrometer-VPT1 (Diabetik Foot Care, Madras Engineering Service, India), perception of 10-g monofilament at 5 standardised plantar locations, and ankle reflex.

Interventions:

Participants were randomly assigned in 1:2 ratio to receive either injection denosumab 60 gm (Group A) or equal volume of normal saline (Group B) subcutaneous over abdomen as a single dose (denosumab and normal saline were provided in similar looking syringe). The investigator administering the treatment, radiologist and the patient were blinded to treatment allocation. A conventional below knee, non-walking, non-removable fibreglass total contact cast (TCC) were provided to all participants irrespective of the group allocation for offloading.

Procedures:

Participants visited the study site initially during screening, randomization and subsequently four weekly for the monitoring of foot temperature. During randomization visit, blood samples were drawn for HbA1c, renal functions, calcium, phosphate and vitamin D. An average of three temperature readings at the afflicted site of the foot were taken and temperature difference (0C) were noted. The study drug or placebo were administered by blinded investigator and TCC was provided. Subsequently, during 4-weekly follow up visits the cast was removed for 30 minutes and skin temperature (mean of three readings) difference was noted. A change of cast was performed four weekly or earlier to avoid "pistoning" effect caused by the edema diminution until clinical remission. Patients with vitamin D deficiency (25 (OH)D3<30 ng/ml were supplemented with weekly oral cholecalciferol 60,000 IU for 8 weeks , then monthly till end of follow up.

A temperature difference of <2C between the afflicted foot and a similar site on the other foot documented twice (four weeks apart) along with the absence of signs of inflammation was considered "clinical remission" of active CN.

Following the clinical remission of active CN, the TCC shall be discontinued, and participants received cast walkers or customised footwear. Subsequently, foot examination shall be performed to monitor for the recurrence of CN (foot temperature assessment), the occurrence of deformities or ulcers (clinical examination), new-onset fractures (radiological assessment)or amputation for a minimum duration of 48 weeks following remission.

• Study Type: Interventional
• Enrollment (Actual): 78
• Phase: Phase 4

Contacts and Locations

Study Locations

• India
  • Chandigarh, India, 160012
    • Deptt of Endocrinology

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diabetes
• Active Charcot neuroarthropathy of either left or right foot
• Chronic Kidney disease defined as eGFR<60 ml/min/m2 and/or Urine protein >300 mg/day
• Presence of all

Exclusion Criteria:

• Active Pedal ulcer
• Active malignancy
• Hypocalcemia
• Primary Hyperparathyroidism
• Pregnancy and Breast Feeding
• Prior treatment with anti-RANKL antibody
• On corticosteroids

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Danosumab; Danosumab 60mg subcutaneous once at diagnosis	Drug: Danosumab; 60 mg subcutaneous Danosumab; Other Names: Drug Arm
Placebo Comparator: Placebo; Similar Volume, and consistency placebo (Normal Saline) subcutaneous once at diagnosis	Other: Normal Saline; Placebo comparator arm; Other Names: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Remission of acute charcot	Proportion of patients achieving remission	48 week

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Remission duration	Remission duration in weeks or months	48 week
Recurrence of CN	Recurrence of active CN defined by temperature >2 C in the affected foot after documenting remission	48 week
Mortality	All cause death	Death due to any cause during the study duration

Collaborators and Investigators

• Sponsor: Postgraduate Institute of Medical Education and Research

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2019
• Primary Completion (Actual): March 31, 2023
• Study Completion (Actual): March 31, 2023

Study Registration Dates

• First Submitted: March 6, 2023
• First Submitted That Met QC Criteria: March 21, 2023
• First Posted (Actual): April 4, 2023

Study Record Updates

• Last Update Posted (Actual): August 30, 2023
• Last Update Submitted That Met QC Criteria: August 28, 2023
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Joint Diseases; Musculoskeletal Diseases; Arthropathy, Neurogenic
• Other Study ID Numbers: DANCN 01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No